Amneal Pharmaceuticals, Inc. (AMRX) Revenue History
Annual and quarterly revenue from 2015 to present
AMRX Revenue Over Time (2015–2025)
AMRX Revenue Growth History
9 of 10 years with positive growth- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- +17.5%
- FY2017 revenue growth
- +1.5%
- FY2018 revenue growth
- +60.9%
- FY2019 revenue growth
- -2.2%
- FY2020 revenue growth
- +22.5%
- FY2021 revenue growth
- +5.1%
- FY2022 revenue growth
- +5.7%
- FY2023 revenue growth
- +8.2%
- FY2024 revenue growth
- +16.7%
- FY2025 revenue growth
- +8.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $862.7M | +10.0% |
| Q2 2026 | $796.2M | +9.9% |
| Q1 2026 | $722.5M | +3.9% |
| Q4 2025 | $814.3M | +11.5% |
| Q3 2025 | $784.5M | +11.7% |
| Q2 2025 | $724.5M | +3.2% |
| Q1 2025 | $695.4M | +5.5% |
| Q4 2024 | $730.5M | +18.4% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
AMRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
AMRX Revenue Analysis (2015–2025)
Current Revenue & Growth
As of November 8, 2026, Amneal Pharmaceuticals, Inc. (AMRX) generated trailing twelve-month (TTM) revenue of $3.20 billion, reflecting solid growth of +10.0% year-over-year. The most recent quarter (Q3 2026) recorded $862.7 million in revenue, up 8.4% sequentially.
Historical Growth Trajectory
AMRX's 5-year compound annual growth rate (CAGR) stands at +8.7%, indicating steady revenue expansion. The 3-year CAGR of +10.9% exceeds the 5-year average, indicating an acceleration in the most recent period. Amneal Pharmaceuticals, Inc.'s highest annual revenue of $3.02 billion was recorded in 2025, an all-time high.
Revenue by Segment
AMRX's revenue is primarily driven by Specialty Segment (100%). With over half of revenue concentrated in Specialty Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including TEVA (+2.7% YoY), VTRS (+4.3% YoY), and PRGO (-4.5% YoY) — AMRX has outperformed the peer group in revenue growth. Compare AMRX vs TEVA →
AMRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AMRXCurrent | $3.2B | +10.0% | +8.7% | 14.0% | |
 TEVA | $17.3B | +2.7% | +0.7% | 12.5% | |
 VTRS | $14.3B | +4.3% | +3.7% | -18.6% | |
 PRGO | $4.3B | -4.5% | +0.8% | 8.1% | |
 PAHC | $1.5B | +10.1% | +12.7% | 13.1% |
AMRX Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.02B | +8.0% | $1.14B | 37.6% | $423.1M | 14.0% |
| 2024 | $2.79B | +16.7% | $1.02B | 36.5% | $249.3M | 8.9% |
| 2023 | $2.39B | +8.2% | $863.9M | 36.1% | $204.4M | 8.5% |
| 2022 | $2.21B | +5.7% | $791.5M | 35.8% | $-94,928,000 | -4.3% |
| 2021 | $2.09B | +5.1% | $769.0M | 36.7% | $152.7M | 7.3% |
| 2020 | $1.99B | +22.5% | $628.4M | 31.5% | $91.2M | 4.6% |
| 2019 | $1.63B | -2.2% | $353.0M | 21.7% | $-248,682,000 | -15.3% |
| 2018 | $1.66B | +60.9% | $716.4M | 43.1% | $-19,673,000 | -1.2% |
| 2017 | $1.03B | +1.5% | $526.2M | 50.9% | $245.1M | 23.7% |
| 2016 | $1.02B | +17.5% | $597.5M | 58.7% | $284.9M | 28.0% |
| 2015 | $866.3M | - | $499.2M | 57.6% | $227.2M | 26.2% |
AMRX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AMRX — Frequently Asked Questions
Quick answers to the most common questions about buying AMRX stock.
Is AMRX's revenue growth accelerating or slowing?
AMRX revenue growth is holding steady at +10.0% year-over-year. TTM revenue is $3.2B. The current growth rate closely tracks the 5-year CAGR of +8.7%, signalling consistent execution.
What is AMRX's revenue history from 2015 to 2026?
Amneal Pharmaceuticals, Inc. (AMRX) revenue history spans 2015 to 2026. TTM revenue as of 2026 is $3.2B, growing at +10.0% YoY. The 5-year CAGR is +8.7%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is AMRX's long-term revenue growth rate (CAGR)?
Amneal Pharmaceuticals, Inc.'s 5-year revenue CAGR of +8.7% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +10.0% is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for AMRX.
Why does AMRX's quarterly revenue fluctuate?
AMRX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Amneal Pharmaceuticals, Inc.'s revenue data from 2015 to 2026 shows full historical quarterly detail on this page.
How is AMRX's revenue distributed by segment?
AMRX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does AMRX's revenue compare to industry peers?
Amneal Pharmaceuticals, Inc. (AMRX) with TTM revenue of $3.2B and +10.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.